DATA SHEET - Medsafe
VIREAD data SHEET (14 July 2017) 1 of 46 data SHEET 1. VIREAD ( TENOFOVIR DISOPROXIL FUMARATE 300 mg) TABLETS 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Tenofovir disoproxil fumarate 300 mg For full list of excipients, see section 3. PHARMACEUTICAL FORM Film-coated tablet. VIREAD tablets are light blue and almond-shaped. Each tablet is debossed on one side with the markings GILEAD and 4331 and on the other side with the marking 300 . 4. CLINICAL PARTICULARS Therapeutic Indications VIREAD in combination with other antiretroviral agents is indicated for the treatment of HIV-infected adults and paediatric patients 12 years of age and older. VIREAD is indicated for the treatment of chronic hepatitis B in adults and in paediatric patients 12 years of age and older. Dose and method of administration Adults: The recommended dose is 300 mg (one tablet) once daily taken orally with or without food.
VIREAD Data Sheet (24 April 2019) 4 of 46 Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphataemia), has been reported in association with the use of
Download DATA SHEET - Medsafe
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: